Blocking a central mediator in the inflammation of gout patients (NLRP3 inflammasome) prevents cardiovascular events by activating the cytokine interleukin-1β, which affects the development of atherothrombotic plaques [27, 31]. The gene discussed is NLRP3; the disease is gout.